Gregory Pacyk (@GPacyk) header
Gregory Pacyk (@GPacyk) profile picture
Aalborg, Danmark
Joined October 2013
Gregory Pacyk retweeted
New consensus statement from EASO, @efad_org and @ECPObesity on the use of incretin-based therapies (IBTs): Nutritional, Functional and Psychological Considerations for Obesity Management Medications in Adults Read more: easo.org/nutritional-functio…
28
74
3,991
All patients with #Addison's disease should be given a #steroid emergency card and provided with and trained to use a glucocorticoid injection kit thelancet.com/journals/landi… primary #adrenal insufficiency
3
4
1
24
2,089
Gregory Pacyk retweeted
Obesity is a chronic, multifactorial disease, yet we often treat it without systematically assessing what is driving it. CheckCausesObesity.com is a new science based tool designed to screen for potential contributors to obesity and relevant comorbidities, helping move us toward more individualized, comprehensive obesity care. nature.com/articles/s41574-0…
3
64
2
217
10,746
The increasing number of men presenting with functional #hypogonadism poses diagnostic challenges due to subtle clinical features and controversies in diagnostic serum #testosterone cut-offs thelancet.com/journals/landi… #MensHealth
17
61
3,625
Obesity treatment is expected to shift gradually from a one-size-fits-all approach towards more personalised medicine, in which the obesity phenotype and presence of related conditions will determine the treatment strategy thelancet.com/journals/landi… #obesity #GLP-1 receptor agonists
3
58
3
138
17,996
New—Is weight cycling clinically harmful? thelancet.com/journals/landi… #weightloss #weight regain #obesity #overweight #dieting #exercise #GLP-1 receptor agonists
22
74
5,477
Natural history of #thyroid function in #ageing: an individual participant data analysis of 137 488 participants from 31 prospective cohort studies thelancet.com/journals/landi… #olderadults #TSH
1
8
35
2,000
#Catecholamine excess is an uncommon but severe cause of #hypertension, sometimes demanding unique considerations that guide management, with the occasional use of less common agents for treatment thelancet.com/journals/landi… #phaeochromocytomas #Paragangliomas #PPGLs #adrenal
2
51
1
143
7,117
Gregory Pacyk retweeted
𝗧𝗵𝗲 𝗘𝗳𝗳𝗲𝗰𝘁 𝗼𝗳 𝗚𝗟𝗣-𝟭 𝗥𝗲𝗰𝗲𝗽𝘁𝗼𝗿 𝗔𝗴𝗼𝗻𝗶𝘀𝘁𝘀 𝗼𝗻 𝗚𝗹𝘆𝗰𝗮𝘁𝗲𝗱 𝗛𝗲𝗺𝗼𝗴𝗹𝗼𝗯𝗶𝗻 𝗟𝗲𝘃𝗲𝗹𝘀 Randomized, placebo-controlled trials of the glucagon-like peptide-1 (GLP-1) receptor agonists have provided strong evidence to support their use — in fact, they have presaged a mini-revolution in how type 2 diabetes is managed. 👉 nejm.org/doi/full/10.1056/NE… Tirzepatide was the first dual GLP-1 and glucose-dependent insulinotropic peptide receptor agonist approved for the treatment of type 2 diabetes on the basis of the SURPASS-1 (Tirzepatide [LY3298176] in Participants with Type 2 Diabetes Not Controlled with Diet and Exercise Alone) trial, a randomized, placebo-controlled trial of tirzepatide (administered in weekly doses of 5 mg, 10 mg, or 15 mg) paired with metformin for treatment of type 2 diabetes (seen in figure). Tirzepatide reduced glycated hemoglobin levels by as much as 2 percentage points and was superior to placebo at all dose levels. At 40 weeks, nearly 90% of participants had glycated hemoglobin levels of less than 7.0%, a change that was associated with profound weight loss. Read the Review Article “GLP-1 Receptor Agonists” by Clifford J. Rosen, MD, and Julie R. Ingelfinger, MD, from @TuftsMedSchool and the Maine Medical Center Institute for Research: nejm.org/doi/full/10.1056/NE…
2
168
8
498
35,379
The story of amylin: from physiology to therapy @NatMetabolism nature.com/articles/s42255-0…
1
22
54
2,074
New—Tubeless #automated #insulin #delivery versus multiple daily injections in children and adults with type 1 #diabetes with elevated HbA1c (RADIANT): a multicentre, international, parallel-group, open-label, randomised, controlled trial thelancet.com/journals/landi… #T1D #AID
1
2
1
20
2,413
1
12
1
44
3,163
New—Clinical features, investigation, and management of Addison's disease thelancet.com/journals/landi… #adrenal insufficiency
40
128
7,169
⚖️💊 What happens when weight-loss drugs stop? The uncomfortable truth This 2026 BMJ systematic review and meta-analysis delivers one of the clearest reality checks yet on weight regain after stopping weight-management medications (WMMs), including GLP-1 and dual incretin therapies . 🔍 What was studied Across 37 studies (63 treatment arms, 9,341 adults) with overweight or obesity, the authors quantified how fast weight returns after discontinuing medication, and compared this with regain after behavioural weight-management programmes (BWMPs). Follow-up extended up to two years after treatment cessation. 📉 The headline finding On average, people regain 0.4 kg per month after stopping WMMs. At this pace, baseline weight is reached again within ~1.7 years. For newer, highly effective incretin drugs (e.g. semaglutide, tirzepatide), regain is even faster—up to 0.8 kg/month, with return to baseline in ~1.5 years. 🫀 Metabolic benefits fade too Improvements in HbA1c, fasting glucose, lipids, and blood pressure closely track weight. Once medication stops, cardiometabolic markers steadily worsen, returning to baseline within ~1.4 years. Weight loss without maintenance = temporary risk reduction. ⚠️ Worse than lifestyle alone When directly compared, weight regain after stopping drugs was significantly faster than after stopping behavioural programmes, independent of how much weight was initially lost. Bigger losses tended to rebound faster—biology pushes back hard. 🧠 Why this matters Obesity behaves like a chronic, relapsing disease. Short-term pharmacotherapy without a long-term plan risks disappointment, lost benefit, and misaligned expectations—for patients and health systems alike. 🔮 Bottom line Weight-loss drugs are powerful—but they don’t “cure” obesity. Their benefits persist only while treatment continues, or if embedded in a sustained, comprehensive strategy. Stopping therapy doesn’t just pause progress—it reverses it 🚨
16
142
9
323
27,781
Gregory Pacyk retweeted
Natural daylight and improved glucose control in Type 2 diabetes cell.com/cell-metabolism/ful… @Cell_Metabolism
7
197
12
799
51,169
Precision Obesity Medicine: A Phenotype Guided Framework For Pharmacologic Therapy Across The Lifespan Review link.springer.com/article/10… @DrNadolsky @DrKarlNadolsky @drmatthewnagra @NutritionMadeS3 @BevTchangMD @MichaelAlbertMD
3
47
3
197
14,577
The evolution of C-peptide's role in diabetes care. #currentopinioninendocrinology journals.lww.com/co-endocrin…
85
2
264
14,112